BRAF and malignant colon neoplasm: Importantly, we detected an upsurge in the expression levels and activity of c-Myc in both resistant cell lines after the PLX4032 challenge, which implies that c-Myc plays an important role in modulating vemurafenib resistance in BRAF mutant colon cancer cells.